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Aluminium phosphide is commonly used as an insecticide and can be toxic to humans at the cellular level by
interfering with mitochondrial energy metabolism. We report on three cases of severe aluminium phosphide cardio-
toxicity, resulting in severe decrease in both ventricular heart functions. The first case succumbed to intractable
ventricular arrhythmias complicated by multi-organ failure before she died; while the other two cases required invasive
hemodynamic support and eventually improved over the course of 10–14 days. We describe our experience and the
challenges faced while managing one of them.
Crown Copyright  2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.
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phosphide toxicityEstablished facts
Established fact 1: Aluminium phosphidetoxicity causes cardiac toxicity.
Established fact 2: No known antidote for this
type of poisoning at present.Novel insights
Novel addition 1: Aluminium phosphide causes
reversible cardiac toxicity whose effects may last
10–14 days. According to our local experience,
optimal aggressive hemodynamic supportthroughout the injury period results in better
outcomes.
Novel addition 2: To our knowledge, this is one
of the first reported cases of aluminium phos-
phide poisoning treated using a combination of
intra-aortic balloon pump and extra corporeal
membrane oxygenation to treat severe prolonged
cardiogenic shock.
Novel addition 3: Drugs which work at the mito-
chondrial level to improve the metabolism of car-
diac muscle cells may be a useful adjunct to
invasive hemodynamic support in such severe
cases of poisoning.
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SEVERE REVERSIBLE MYOCARDIAL INJURY
ASSOCIATED WITH ALUMINIUM PHOSPHIDE
TOXICITY: A CASE REPORT AND REVIEW OF LITERATURECase report
A 45-year-old woman, accompanied by her se-
ven-year-old son and 11-year-old daughter, pre-
sented to the emergency department with vague
symptoms of fatigue, nausea and recurrent vomit-
ing. They were initially treated with intravenous
normal saline, anti-emetics and discharged home
after several hours. The next day, they presented
with severe deterioration in clinical status as evi-
denced by hypotension, tachypnea and tachycar-
dia (See Fig. 1).
The 11-year-old daughter followed a steeply
declining clinical course. Within 12 h she was
intubated, developed intractable ventricular
tachycardia twice, requiring prolonged CPR and
multiple DC shocks, followed by persistent hypo-
tension and anuria despite multiple inotropes.
She succumbed to her fate and died within 36 h.
The 6-year-old son had a bedside echo showing
left ventricular ejection fraction (LVEF) of 35% and
was started on milrinone infusion 0.25/kg/min. He
was later moved to another facility for further
treatment which included extra corporeal mem-
brane oxygenation (ECMO) (See Fig. 2).
Our index patient had been initially started on
triple inotropes (Dobutamine 20 lg/kg/min,
Dopamine 20 lg/kg/min, Noradrenaline 8 lg/h),
which did not deter her hemodynamic deteriora-
tion. Her initial bedside echocardiogram showed
severe biventricular systolic dysfunction, and
LVEF of 25–30%. No valvular abnormality, no
pericardial effusion. On the second day, she re-
quired intubation, and an intra-aortic balloon
pump (IABP) was inserted. Six hours later, she
continued to be anuric with high oxygen require-
ment and low blood pressure, and she was placed
on ECMO via right femoral vein and artery access,
while her IABP was kept via left femoral artery ac-
cess. Cardiac output was set at 3.7 l/min. Unfrac-Figure 1a. Initial ECG showing minimal QRS prolontionated heparin was initiated by bolus 1000
units followed by 800 units/h, with target ACT of
150–180. She was started on 8 L/min oxygen. The
patient also required CRRT during the initial two
days due to acute kidney injury and anuria (See
Fig. 3).
Medication wise, the patient was started early
on high dose L-carnitine 1 g three times a day
for 10 days along with broad spectrum antibiotics.
Initial hypo-magnesemia was treated intrave-
nously by supplemental magnesium sulphate
(2 gm) daily for four days. She was also started
on Candesartan 2 mg bid, Spironolactone
12.5 mg daily, and Carvedilol 3.125 mg bid (See
Fig. 4).
Over the next day, the patient was weaned off
inotropes. Daily bedside echo via sub-costal
window showed initial deterioration of overall
cardiac function up to day 3; in the form of severe
global myocardial hypokinesia/akinesia. LVEF
had reached a nadir of 10%; right ventricular dys-
function was evidently moderately severe. Slow
improvement ensued over the next 10 days with
LVEF rising up to 45–50%. Initial improvement
had commenced in the lateral and inferior left
ventricular walls, while last walls to improve were
the septal and anterior walls. Initial echo pictures
had also shown a mild increase of wall thickness
involving myocardial mid and distal segments
(up until the apex). As heart function improved,
this regressed. A repeat echo performed 3 weeks
after index event confirmed the almost complete
resolution of systolic dysfunction in all wall seg-
ments except distal apex. There was resolution of
all the myocardial increased thickness except at
the distal lateral wall segment where it persisted.
ECG at presentation showed normal sinus
rhythm, normal PR interval and partial left bundle
branch block with QRS duration of 94 ms. Overgation and non-specific ST and T wave changes.
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Figure 1b. Latest ECG showing shortening of QRS duration and resolution of ST/T wave changes.
Figure 3a. Initial 4 chamber view showing dilated LV with poor
systolic function.
Figure 3b. Resolution of lateral and inferior WMA and improved LV
systolic function.
Figure 2b. Final view via echo showing collapsing IVC and resolu-
tion of thrombus.
Figure 2a. Initial dilated IVC with thrombus.
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while a pattern of T wave inversions evolved in
antero-lateral leads. Ten days later, ECG showed
complete resolution of these changes.
After day 10, the patient was weaned off IABP
and the next day off ECMO with accesses closed
surgically. Bedside echo then showed a small
pedunculated thrombus in the IVC, 2–3 cm from
C
A
SE
 R
EP
O
RT
Figure 4a. Initial short axis view showing WMA in inferior, lateral
walls.
Figure 4b. Final short axis view showing smaller LV cavity with
resolution of WMA.
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TOXICITY: A CASE REPORT AND REVIEW OF LITERATUREits entrance into the right atrium. Patient had ini-
tially developed transient slurring of speech and
increased tremors which improved over 2 days.
A CT of the brain showed no evidence of CVA
and this was attributed to side effects of poly
pharmacy (especially haloperidol). Patient was fi-
nally discharged home on warfarin, target INR
2.0. Three weeks later, a repeat echo showed reso-
lution of the IVC thrombus with shrinking of IVC,
and warfarin was then discontinued.
A police report had noted traces of aluminium
phosphide at the patient’s flat. The source of alu-
minium phosphide was from an insecticide used
3 days earlier. They were told to leave the flat
and close all windows and ventilator ducts, which
the mother and children did, but only after several
hours of inhaling the pungent odor.Discussion
Aluminium phosphide (AlP) is an insecticide,
rodenticide and fungicide, commonly used in the
Indian subcontinent as well as in other developing
countries. Since the 1970s there have been
increasing reports of AlP poisoning with a mortal-
ity rate of 70% [1]. Boogle et al. reported that the
majority of poisoning cases were accidental [2].
The toxic effects of the AlP are due to deadly
phosphine gas, which, when liberated, reacts with
water or hydrochloric acid in the stomach [3].
Phosphine gas (PH3) is the active pesticide com-
ponent of AlP, which is rapidly absorbed by inha-
lation, ingestion, and skin or mucosal contact [3].
PH3 works at the mitochondrial level where it
can rapidly perturb mitochondrial conformation
and inhibit oxidative respiration by up to 70%, se-
verely decreasing mitochondrial membrane po-
tential [4]. PH3 mainly inhibits cytochrome C
oxidase (Complex IV) and decreases Complex I
and Complex II activity, resulting in decreased
ATP formation [5]. This results in the slowing
down of the electron flow with resultant electron
leakage, initiating reactive oxygen species produc-
tion (ROS). PH3 further inhibits the antioxidant
enzymes, catalase and peroxidase, decreasing the
scavenging of ROS [6].
Clinically, cardiac manifestations among cases
of poisoning are due to PH3 induced myocardial
damage. In fact, acute cardiovascular collapse is
the most common mode of presentation seen in
60% to 100% of cases [10]. Autopsy results show
congestion of heart, separation and fragmentation
of myocardial fibers, nonspecific vacuolation of
myocytes, focal necrosis as well as neutrophilic
and eosinophilic infiltration [7]. The focal myocar-
dial necrosis and changes in membrane action
potentials result in non-specific ST-T wave
changes in the EKG [8].
In our patient, the EKG showed changes initially
as incomplete LBBB, followed by narrowing of
QRS complex and developing repolarization
changes in the antero-lateral leads, which normal-
ized in 10 days. Singh et al. [9] reported that EKG
changes reverts to normal pattern within 10–
14 days in survivors.
Echocardiogram showed a drastic reduction in
systolic function with global severe hypokinesia.
Similar cases have been reported with significant
decrease in ejection fraction [2]. Bhasin et al.
demonstrated a similar pattern of global hypoki-
nesia of the LV walls in 80% of their cases [11].
Echocardiographic findings correlated with
hemodynamic stability and our patient showed
remarkable gradual improvement in left
C
A
SE R
EPO
RT
220 ELABBASSI ET AL
SEVERE REVERSIBLE MYOCARDIAL INJURY
ASSOCIATED WITH ALUMINIUM PHOSPHIDE
TOXICITY: A CASE REPORT AND REVIEW OF LITERATURE
J Saudi Heart Assoc
2014;26:216–221ventricular ejection fraction by the 10th day. Gup-
ta et al. had reported normalization of ECHO find-
ings in AlP survivors by the 5th day [12].
Laboratory parameters had shown initial hypo-
magnesemia and were aggressively treated. Mag-
nesium ions help in scavenging free radicals and
acts as an anti-arrhythmic agent. Previous reports
suggest it may be beneficial in treating AlP poi-
soning cases, [13] while others found it confers
no difference on survival [14].
Siwach et al. [15] noted that ventricular tachy-
cardia occurs in 40% of AlP-poisoned patient
cases, ventricular fibrillation in 23.3%, supraven-
tricular tachycardia in 46.7%, and atrial flutter/
fibrillation in 20%. Our index cases did not suffer
such complications possibly related to early
aggressive intervention with correction of electro-
lyte imbalance. The daughter notably suffered
refractory arrhythmias and eventually expired
due to multi-organ failure. She also had hypo-
magnesemia and had commenced treatment for
that.
The cardiac function of both the mother and son
improved within 10–14 days. Akkaoui et al. [16]
reported two cases of aluminium phosphide
poisoning with reversible myocardial injury,
which improved after 7–10 days.
L-carnitine is an essential co-factor in fatty acid
metabolism which is the primary source of energy
for cardiac muscles, and where it shuttles long-
chain fatty acids and activated acetate across the
inner mitochondrial membrane [17]. A decrease
in fatty acid oxidation after myocardial ischemia
leads to accumulation of long-chain acyl-CoA es-
ters, which inhibits adenine nucleotide transloca-
tion, with a net result that lowers the energy
charge of the cell, adversely affecting muscle con-
traction and electrical conduction [18].
Liedtke et al. [19] demonstrated that use of L-
carnitine in ischemic hearts preserves mechanical
function under conditions of excess free fatty acid
(FFA), by modifying the toxic effects of FFA
intermediates. CEDIM trial [20] reported that
treatment with L-carnitine in ischemic hearts
resulted in a significant reduction of left ventricu-
lar dilatation, with significant reduction in both
end-diastolic and end-systolic volumes in the
levocarnitine-treated group. No modification of
left ejection fraction was observed, while the inci-
dence of death, congestive heart failure, and
ischemic events were fewer.
Aluminium phosphide toxicity interferes with
the electron transport chain and gives rise to myo-
cardial necrosis similar to what occurs during
ischemia. Such an event leads to the accumulationof long chain acyl-CoA metabolites. A decrease of
the impact of these additional metabolites on the
cardiac metabolism promotes better outcomes.
The use of L-carnitine in aluminium phosphide
poisoning has not previously been reported to
the best of our knowledge. Whether its use influ-
enced the positive outcome in our case is anec-
dotal and hypothesis-generating at best, and
remains to be tested in a randomized trial.Conclusion
Aluminium phosphide poisoning can result in
severe cardiac toxicity. This may be reversible
provided the patient can be sustained during the
‘‘insult period’’. At present, no specific antidote
for this poisoning is known, and treatment strat-
egy is supportive until the injury induced by the
active compound (phosphine) subsides. Patients
with severe intoxication benefit from aggressive
hemodynamic support, as in our case. Our use
of L-carnitine for this patient with encouraging re-
sult needs further validation by others, as it may
be a useful adjunct to IABP and ECMO alongside
other conventional treatments for heart failure.
This remains to be verified.Conflict of interest
None.Disclosure
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